http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 03 Feb 2026 11:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Press+Releases/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html <p class="bwalignc"> <i>Authorization clears the way for customers to enter Brazil’s $40 billion pharmaceutical market </i> </p> <p> SEATTLE--(BUSINESS WIRE)-- The <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agcbio.com%2Ffacilities%2Fseattle&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Seattle+facility+of+AGC+Biologics&amp;index=1&amp;md5=ee4947b3d28fff30464665de4b9bc31c" shape="rect"><b>Seattle facility of AGC Biologics</b></a>, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from<b> </b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gov.br%2Fanvisa%2Fpt-br%2F&amp;esheet=54411942&amp;newsitemid=20260203117569&amp;lan=en-US&amp;anchor=Ag%26ecirc%3Bncia+Nacional+de+Vigil%26acirc%3Bncia+Sanit%26aacute%3Bria+%28Anvisa%29&amp;index=2&amp;md5=bdeebf10a885f33899e532f7ca010c80" shape="rect"><b>Agência Nacional de Vigilância Sanitária (Anvisa)</b></a>, Brazil’s health regulatory authority. The authorization allows biologics and biosimilars produced at the site to be commercialized in Brazil, the largest pharmaceutical market in South America, further extending the global reach of AGC Biologics’ customers. </p><p> “This certification ensures that our customers are able to deliver product to patients in need of http://www.streetinsider.com/Business+Wire/AGC+Biologics+Seattle+Site+Now+Certified+to+Manufacture+Biologics+for+Largest+Pharmaceutical+Market+in+South+America/25936374.html Tue, 03 Feb 2026 11:00:00 -0500 5201 A.06822034 A.10912314 ASGLY O.05105704 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html <p> <i>This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved</i> </p> <p> MILAN--(BUSINESS WIRE)-- With the decision by the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome&amp;esheet=54398643&amp;newsitemid=20260116594628&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration&amp;index=1&amp;md5=9d99f57466715e162a19e2109cd3907a" shape="rect">U.S. Food and Drug Administration</a> and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide. </p><p> Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html Fri, 16 Jan 2026 14:00:00 -0500 5201 A.05532209 A.06822034 A.10912314 A.41307835 A.60012004 ASGLY O.01239210 O.01304637 O.05105704 O.10577833 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html <p> <i>This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved</i> </p> <p> MILAN--(BUSINESS WIRE)-- With the decision by the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome&amp;esheet=54398643&amp;newsitemid=20260116594628&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration&amp;index=1&amp;md5=9d99f57466715e162a19e2109cd3907a" shape="rect">U.S. Food and Drug Administration</a> and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide. </p><p> Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html Fri, 16 Jan 2026 14:00:00 -0500 5201 A.05532209 A.06822034 A.10912314 A.41307835 A.60012004 ASGLY O.01239210 O.01304637 O.05105704 O.10577833 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html <p> <i>This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved</i> </p> <p> MILAN--(BUSINESS WIRE)-- With the decision by the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome&amp;esheet=54398643&amp;newsitemid=20260116594628&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration&amp;index=1&amp;md5=9d99f57466715e162a19e2109cd3907a" shape="rect">U.S. Food and Drug Administration</a> and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide. </p><p> Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html Fri, 16 Jan 2026 14:00:00 -0500 5201 A.05532209 A.06822034 A.10912314 A.41307835 A.60012004 ASGLY O.01239210 O.01304637 O.05105704 O.10577833 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html <p> <i>This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved</i> </p> <p> MILAN--(BUSINESS WIRE)-- With the decision by the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome&amp;esheet=54398643&amp;newsitemid=20260116594628&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration&amp;index=1&amp;md5=9d99f57466715e162a19e2109cd3907a" shape="rect">U.S. Food and Drug Administration</a> and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide. </p><p> Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html Fri, 16 Jan 2026 14:00:00 -0500 5201 A.05532209 A.06822034 A.10912314 A.41307835 A.60012004 ASGLY O.01239210 O.01304637 O.05105704 O.10577833 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html <p> <i>This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved</i> </p> <p> MILAN--(BUSINESS WIRE)-- With the decision by the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome&amp;esheet=54398643&amp;newsitemid=20260116594628&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration&amp;index=1&amp;md5=9d99f57466715e162a19e2109cd3907a" shape="rect">U.S. Food and Drug Administration</a> and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide. </p><p> Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html Fri, 16 Jan 2026 14:00:00 -0500 5201 A.05532209 A.06822034 A.10912314 A.41307835 A.60012004 ASGLY O.01239210 O.01304637 O.05105704 O.10577833 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html <p> <i>This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved</i> </p> <p> MILAN--(BUSINESS WIRE)-- With the decision by the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome&amp;esheet=54398643&amp;newsitemid=20260116594628&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration&amp;index=1&amp;md5=9d99f57466715e162a19e2109cd3907a" shape="rect">U.S. Food and Drug Administration</a> and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide. </p><p> Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html Fri, 16 Jan 2026 14:00:00 -0500 5201 A.05532209 A.06822034 A.10912314 A.41307835 A.60012004 ASGLY O.01239210 O.01304637 O.05105704 O.10577833 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html <p> <i>This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved</i> </p> <p> MILAN--(BUSINESS WIRE)-- With the decision by the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome&amp;esheet=54398643&amp;newsitemid=20260116594628&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration&amp;index=1&amp;md5=9d99f57466715e162a19e2109cd3907a" shape="rect">U.S. Food and Drug Administration</a> and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide. </p><p> Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html Fri, 16 Jan 2026 14:00:00 -0500 5201 A.05532209 A.06822034 A.10912314 A.41307835 A.60012004 ASGLY O.01239210 O.01304637 O.05105704 O.10577833 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html <p> <i>This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved</i> </p> <p> MILAN--(BUSINESS WIRE)-- With the decision by the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome&amp;esheet=54398643&amp;newsitemid=20260116594628&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration&amp;index=1&amp;md5=9d99f57466715e162a19e2109cd3907a" shape="rect">U.S. Food and Drug Administration</a> and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide. </p><p> Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html Fri, 16 Jan 2026 14:00:00 -0500 5201 A.05532209 A.06822034 A.10912314 A.41307835 A.60012004 ASGLY O.01239210 O.01304637 O.05105704 O.10577833 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html <p> <i>This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved</i> </p> <p> MILAN--(BUSINESS WIRE)-- With the decision by the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome&amp;esheet=54398643&amp;newsitemid=20260116594628&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration&amp;index=1&amp;md5=9d99f57466715e162a19e2109cd3907a" shape="rect">U.S. Food and Drug Administration</a> and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide. </p><p> Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html Fri, 16 Jan 2026 14:00:00 -0500 5201 A.05532209 A.06822034 A.10912314 A.41307835 A.60012004 ASGLY O.01239210 O.01304637 O.05105704 O.10577833 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html <p> <i>This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved</i> </p> <p> MILAN--(BUSINESS WIRE)-- With the decision by the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome&amp;esheet=54398643&amp;newsitemid=20260116594628&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration&amp;index=1&amp;md5=9d99f57466715e162a19e2109cd3907a" shape="rect">U.S. Food and Drug Administration</a> and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide. </p><p> Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html Fri, 16 Jan 2026 14:00:00 -0500 5201 A.05532209 A.06822034 A.10912314 A.41307835 A.60012004 ASGLY O.01239210 O.01304637 O.05105704 O.10577833 O.20026344 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html <p> <i>This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved</i> </p> <p> MILAN--(BUSINESS WIRE)-- With the decision by the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-gene-therapy-treatment-wiskott-aldrich-syndrome&amp;esheet=54398643&amp;newsitemid=20260116594628&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration&amp;index=1&amp;md5=9d99f57466715e162a19e2109cd3907a" shape="rect">U.S. Food and Drug Administration</a> and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics’ Milan Cell and Gene Center of Excellence announced it will continue to support the commercial development of this vital, life-changing therapy for young patients worldwide. </p><p> Wiskott-Aldrich syndrome is a rare immune disorder affecting approximately 1 in 250,000 live male births, leading to http://www.streetinsider.com/Press+Releases/AGC+Biologics+Celebrates+U.S.+and+EU+Approval+of+Fondazione+Telethon%E2%80%99s+Waskyra%E2%84%A2+Treatment+for+Wiskott-Aldrich+Syndrome/25859558.html Fri, 16 Jan 2026 14:00:00 -0500 5201 A.05532209 A.06822034 A.10912314 A.41307835 A.60012004 ASGLY O.01239210 O.01304637 O.05105704 O.10577833 O.20026344 O.40439785